Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 5, 2003, Pages 633-639

  Lester, Henry A ^a   Fonck, Carlos ^a   Tapper, Andrew R ^a   McKinney, Sheri ^a   Damaj, M Imad ^b   Balogh, Seth ^c   Owens, Jeremy ^c   Wehner, Jeanne M ^c   Collins, Allan C ^c   Labarca, Cesar ^a  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Epilepsy; Excitotoxicity; Nicotine addiction; Nicotinic acetylcholine receptors; Smoking cessation

Indexed keywords

NICOTINE; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT;

ALLELE; ANTINOCICEPTION; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; ELECTROPHYSIOLOGY; GENE EXPRESSION; HYPOTHERMIA; LETHALITY; MOUSE STRAIN; POINT MUTATION; REVIEW; SEIZURE;

ANIMALS; BODY TEMPERATURE; BRAIN; MICE; MICE, MUTANT STRAINS; MODELS, ANIMAL; NICOTINE; NICOTINIC AGONISTS; POINT MUTATION; RECEPTORS, NICOTINIC; SEIZURES;

EID: 0142091438     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Lester HA: Heterologous expression of excitability proteins: Route to more specific drugs? Science (1988) 241(4869):1057-1063.
2. Rose JE, Behm FM, Westman EC: Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacol Biochem Behav (2001) 68(2):187-197.
3. 7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. J Neurochem (2000) 74(5):2154-2166. The first paper reporting a hypersensitive knockin mouse strain. The allele causes neonatal lethality if not attenuated; the hypersensitivity extends to the level of single-cell electrophysiology, and expression of other nicotinic subunits is unaltered.
4. 9′Ser strain, and the only presentation, to date, on the behavioral aspects of a hypersensitive nAChR mouse strain. Although the knockin mice display nearly normal behavioral phenotypes in several tests, increased anxiety is a striking behavioral phenotype.
5. 7 nicotinic acetylcholine receptor mutation. Mol Pharmacol (2002) 61(3):695-705.
6. Marubio LM, del Mar Arroyo-Jimenez M, Cordero-Erausquin M, Lena C, Le Novere N, de Kerchove d'Exaerde A, Huchet M, Damaj MI, Changeux JP: Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (1999) 398(6730):805-810.
7. 7 neuronal nicotinic acetylcholine receptor lack α-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci (1997) 17(23):9165-9171.
8. 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci (2000) 20(17):6431-6441.
9. 2-subunit in specific neuronal populations. High-affinity nAChRs expressed on corticothalamic neurons during development were critical for baseline passive avoidance, and provide a potential substrate for changes induced by prenatal nicotine exposure that cause long-term behavioral and cognitive deficits.
10. 7 nAChR conducted with net charge analysis. Br J Pharmacol (2002) 137(1):49-61.
11. Dani JA, Ji D, Zhou FM: Synaptic plasticity and nicotine addiction. Neuron (2001) 31(3):349-352.
12. Zhou FM, Wilson CJ, Dani JA: Cholinergic Interneuron characteristics and nicotinic properties in the striatum. J Neurobiol (2002) 53(4):590-605.
13. Picciotto MR, Corrigall WA: Neuronal systems underlying behaviors related to nicotine addiction: Neural circuits and molecular genetics. J Neurosci (2002) 22(9):3338-3341.
14. Dani JA, Heinemann S: Molecular and cellular aspects of nicotine abuse. Neuron (1996) 16(5):905-908.
15. 2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 391(6663):173-177.
16. Markou A, Paterson NE: The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat. Nicotine Tob Res (2001) 3(4):361-373.
17. Labarca C, Nowak MW, Zhang H, Tang L, Deshpande P, Lester HA: Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. Nature (1995) 376(6540):514-516.
18. Revah F, Bertrand D, Galzi JL, Devillers-Theiry A, Mulle C, Hussy N, Bertrand S, Bullivet M, Changeux JP: Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. Nature (1991) 353(6347):846-849.
19. Filatov GN, White MM: The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating. Mol Pharmacol (1995) 48(3):379-384.
20. Kearney PC, Zhang H, Zhong W, Dougherty DA, Lester HA: Determinants of nicotinic receptor gating in natural and unnatural side chain structures at the M2 9′ position. Neuron (1996) 17(6):1221-1229.
21. Zhou M, Engel A, Auerbach A: Serum choline activates mutant acetylcholine receptors that cause slow channel congenital myasthenic syndromes. Proc Natl Acad Sci USA (1999) 96(18):10466-10471. Hypersensitivity to ACh alone does not explain the pathophysiology of the slow-channel syndrome. Instead, some slow-channel alleles are also activated by choline at circulating concentrations. Therefore, the slow-channel syndrome may be an excitotoxic disease due to functional constitutive activation.
22. 7 mutant homomeric receptors. Proc Natl Acad Sci USA (1997) 94(4):1539-1543.
23. 4*-knockin strains will provide a suitable model for autosomal dominant nocturnal frontal-lobe epilepsy (ADNFLE).
24. Ji D, Lape R, Dani JA: Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron (2001) 31(1):131-141.
25. 2* receptors occur in both VTA and SNc.
26. 7 nAChRs.
27. 7 nicotinic acetylcholine receptor. Neuroreport (2002) 13(2):191-196.
28. 2 nAChR. Acta Neurol Scand Suppl (2000) 176:68-73.
29. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX: Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res (2000) 113(1-2):199-206.
30. Caggiula AR, Epstein LH, Perkins KA, Saylor S: Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology (1995) 122(3):301-306.
31. Lester HA, Karschin A: Gain of function mutants: Ion channels and G protein-coupled receptors. Annu Rev Neurosci (2000) 23:89-125.
32. Gomez CM, Maselli RA, Groshong J, Zayas R, Wollmann RL, Cens T, Charnet P: Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci (2002) 22(15):6447-6457. This study models the slow-channel myasthenic syndrome in the muscle nAChRs of transgenic mice.
33. Bertrand D, Picard F, Le Hellard S, Weiland S, Favre I, Phillips H, Bertrand S, Berkovic SF, Malafosse A, Mulley J: How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia (2002) 43(Suppl 5):112-122.
34. 2 acetylcholine response. J Physiol (2003) 550(Pt 1):11-26.
35. Panagis G, Nisell M, Nomikos GG, Chergui K, Svensson TH: Nicotine injections into the ventral tegmental area increase locomotion and Fos-like immunoreactivity in the nucleus accumbens of the rat. Brain Res (1996) 730(1-2):133-142.
36. Mathieu-Kia AM, Pages C, Besson MJ: Inducibility of c-Fos protein in visuo-motor system and limbic structures after acute and repeated administration of nicotine in the rat. Synapse (1998) 29(4):343-354.
37. Shim I, Javaid JI, Wirtshafter D, Jang SY, Shin KH, Lee HJ, Chung YC, Chun BG: Nicotine-induced behavioral sensitization is associated with extracellular dopamine release and expression of c-Fos in the striatum and nucleus accumbens of the rat. Behav Brain Res (2001) 121(1-2):137-147.
38. Schwartz RD, Kellar KJ: Nicotinic cholinergic receptor binding sites in the brain: Regulation in vivo. Science (1983) 220(4593):214-216.
39. Marks MJ, Burch JB, Collins AC: Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J Pharmacol Exp Ther (1983) 226(3):817-825.
40. Buisson B, Bertrand D: Nicotine addiction: The possible role of functional upregulation. Trends Pharmacol Sci (2002) 23(3):130-136.
41. Flores CM, Davila-Garcia MI, Ulrich YM, Kellar KJ: Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J Neurochem (1997) 69(5):2216-2219.
42. 2 mRNA levels. J Pharmacol Exp Ther (1996) 278(1):361-369.
43. Miyazawa A, Fujiyoshi Y, Unwin N: Structure and gating mechanism of the acetylcholine receptor pore. Nature (2003) 424(6943):949-955.